Disposable Endoscopes Market Size & Share 2026-2035

Disposable Endoscopes Market Size

The global disposable endoscopes market was valued at USD 2.2 billion in 2025, reflecting accelerating clinical adoption across hospital systems, ambulatory surgical centers, and critical care units worldwide. The market is projected to expand from USD 2.5 billion in 2026 to USD 9.2 billion by 2035, advancing at a compound annual growth rate (CAGR) of 15.7% over the forecast period, according to the latest report published by Global Market Insights Inc.

The sustained growth trajectory is underpinned by converging structural pressures rising incidence of gastrointestinal malignancies and chronic respiratory disease, growing clinical intolerance for healthcare-associated infections linked to inadequately reprocessed reusable devices, and the ongoing migration of procedures from inpatient operating rooms toward outpatient and ambulatory settings. At the technological level, generational improvements in image sensor miniaturization and single-use scope durability have narrowed the performance gap between disposable and traditional reusable systems to the point where adoption decisions are now driven by safety economics rather than image-quality trade-offs.

Disposable Endoscopes Market Trends

Disposable Endoscopes Market Analysis

By Product Type

Bronchoscopes

The bronchoscope segment is the largest product type category in the disposable endoscopes market, accounting for 35.52% of global revenue in 2025 equivalent to approximately USD 781 million and projected to advance at a CAGR of 16.2% through 2035. At the segment level, growth reflects the intersection of three structural forces: the high and rising global burden of respiratory disease and lung cancer; the widespread adoption of bronchoscopic procedures in critical care and ICU settings where infection control is paramount; and the progressive replacement of reusable bronchoscopes following the clinical validation of HD-quality single-use alternatives.

The fundamental shift is that single-use bronchoscopes have moved from niche adoption in high-risk isolation cases to routine clinical use in major procedure centers, with Ambu reporting that single-use bronchoscopes account for approximately 70% of procedures in its established hospital accounts. Key commercial platforms dominating this segment include Ambu's aScope 5 Broncho HD launched February 2025 with a 5.6 mm insertion tube and 2.8 mm working channel Boston Scientific's Exalt Model B, Verathon's B-Flex 2, and Karl Storz's FIVE S 6.5, cleared by the FDA in March 2026 with a 3 mm working channel specifically engineered for ICU secretion management. The bronchoscopes segment is also the most thoroughly validated in peer-reviewed literature, with comparative studies confirming performance equivalence across all six commercially available single-use models assessed in bronchoalveolar lavage scenarios.

The segment's growth through 2035 is expected to be driven by two concurrent dynamics: deepened penetration in established markets as the remaining fraction of reusable bronchoscopes in US and European hospital accounts is converted; and initial-penetration volume in Asia Pacific and Latin American markets, where domestic manufacturers are expanding single-use bronchoscope access at structurally lower price points. From a competitive standpoint, the bronchoscopes sub-market within the broader disposable endoscopes market is the most contested, with five clinically validated products now competing on working channel diameter, image resolution, and digital platform compatibility.

Ureteroscopes

The ureteroscope segment accounted for 15.10% of global disposable endoscopes revenue in 2025 approximately USD 332 million and is projected to advance at a CAGR of 15.9% through 2035. The underlying driver is the globally rising burden of nephrolithiasis, driven by dietary pattern shifts, increasing obesity prevalence, and climate-related environmental changes that concentrate urinary solutes a phenomenon documented in epidemiological surveillance by the National Institute of Diabetes and Digestive and Kidney Diseases.

Ureteroscopic lithotripsy has become the dominant treatment modality for renal and ureteral stones, displacing extracorporeal shock wave lithotripsy in size categories above 10 mm and generating consistent procedure volumes at hospitals and urology centers globally. Ambu's aScope 5 Uretero and Olympus's RenaFlex cleared by the FDA in April 2024 are the segment's leading single-use platforms, representing the two most commercially significant entries in the urology sub-market within the disposable endoscopes space.

The more consequential commercial development in this segment is the expanded FDA clearance of Ambu's aScope 5 Cysto HD for combined ureteroscopy and PCNL procedures making it the first single-use flexible cysto-nephroscope cleared for percutaneous nephrolithotomy in the United States, enabling single-scope management of complex, multi-compartment urological cases that previously required multiple device types. This functional integration is expected to drive incremental procedure volume and average revenue per case in the ureteroscope category through 2027–2028. Olympus's September 2025 global distribution agreement with MacroLux Medical for single-use urology products further signals the commercial maturation of this segment.

Laryngoscopes

The laryngoscope segment represented 11.07% of global disposable endoscopes revenue in 2025 approximately USD 243 million advancing at a projected CAGR of 15.4% through 2035. Demand is anchored in two primary settings: anesthesia and airway management in operating rooms, and emergency airway access in critical care and emergency departments, where contamination risk from shared equipment is particularly acute.

The COVID-19 pandemic served as a structural accelerant for single-use laryngoscope adoption, generating institutional protocols across major hospital systems specifying single-use video laryngoscopes for aerosolizing procedures a standard that persisted post-pandemic as infection prevention programs formalized the practice. Ambu's video laryngoscope platforms, alongside offerings from Verathon, remain commercially prominent. The integration of single-use laryngoscopes with portable video-tower systems has extended adoption into pre-hospital emergency medicine and military casualty care — settings where field-deployment requirements for contamination-free airway management devices map directly onto the single-use value proposition.

Duodenoscopes

The duodenoscope segment represented 9.54% of the disposable endoscopes market in 2025 approximately USD 210 million and is projected to grow at a CAGR of 15%, the most conservative among all product type segments. The relatively moderated CAGR reflects advanced penetration in the United States and Western Europe, where FDA safety communications on reusable duodenoscope contamination risk have already driven substantial market conversion, particularly for ERCP procedures at high-volume academic and tertiary care centers. Boston Scientific's EXALT Model D for which the FDA cleared an updated configuration in March 2025 remains the segment's reference product.

Growth through 2035 is driven by depth-of-penetration in the remaining fraction of ERCP procedures still performed with reusable duodenoscopes, particularly in community hospitals and health systems outside North America and Western Europe where regulatory conversion pressure has been less immediate. Dragonfly Endoscopy's 360° Rotatable Pancreaticobiliary Scope, FDA-cleared in 2025, represents a directional innovation extending single-use cholangioscopy into complex pancreaticobiliary interventions.

Hysteroscopes

The hysteroscope segment accounted for 8.34% of the disposable endoscopes market in 2025 approximately USD 183 million with a projected CAGR of 15.1% through 2035. Demand is supported by the growing recognition of hysteroscopy as the gold standard for intrauterine assessment in diagnostic and therapeutic gynecology, including endometrial polyp removal, submucosal fibroid resection, and investigation of abnormal uterine bleeding. The shift toward office-based and ambulatory hysteroscopy supported by compact, lightweight single-use systems is expanding procedure access beyond hospital gynecology departments into specialist clinic settings. CooperSurgical's TRUCLEAR Hysteroscopic Morcellation System and Karl Storz's ENDOCRAFT series represent the segment's established commercial platforms, with both enabling the procedural economics of office-based settings where single-use devices eliminate the reprocessing infrastructure requirement entirely. Women's health budget expansion in European health systems particularly under the United Kingdom's NHS Gynaecology Improvement Programme is providing additional volume support.

Cystoscopes

The cystoscope segment accounted for 7.32% of the disposable endoscopes market in 2025 approximately USD 161 million with a projected CAGR of 15.8% through 2035. Demand is underpinned by bladder cancer surveillance requirements: bladder cancer is among the most frequently recurring cancers, requiring cystoscopic monitoring at three-to-twelve month intervals for patients on active surveillance. Ambu's aScope 4 Cysto and aScope 5 Cysto HD are the segment's leading platforms. In September 2025, Zenflow received FDA 510(k) clearance for the Zenflow Spring Scope the first single-use cystoscope featuring a 12 French working channel, over 80% larger than prior single-use models extending the procedural scope of single-use cystoscopy into therapeutic interventions previously requiring reusable equipment. The segment benefits from high repeatability of procedure volumes driven by cancer surveillance protocols, providing a predictable demand floor that supports facility procurement planning.

Other Product Types

The other product types segment comprising primarily gastroscopes, colonoscopes, nasopharyngoscopes, and arthroscopes accounted for 13.11% of the disposable endoscopes market in 2025, approximately USD 288 million, with a projected CAGR of 14.7%. Ambu's aScope Gastro, FDA-cleared in 2022, and Olympus's H-SteriScope represent the most widely commercialized platforms in this sub-group. The GI endoscopy portion of this segment is expected to be its primary growth driver, as the commercial infrastructure for single-use colonoscopy and flexible sigmoidoscopy is built out over the forecast period a transition analogous to the bronchoscope adoption curve observed between 2018 and 2023. The arthroscopy sub-category, while nascent, is attracting early commercial investment from orthopedic surgical device companies exploring single-use joint visualization platforms for high-acuity ambulatory surgical settings.

By Clinical Use

The diagnostic segment is the larger of the two clinical use categories, accounting for 61.81% of the disposable endoscopes market in 2025 approximately USD 1.36 billion with a projected CAGR of 15.5% through 2035. Diagnostic procedures encompass bronchoscopy for lung cancer evaluation and biopsy, upper GI endoscopy for Barrett's esophagus surveillance, colonoscopy for colorectal cancer screening, cystoscopy for bladder cancer monitoring, and hysteroscopy for uterine assessment.

The volume base for diagnostic endoscopy is structurally supported by national cancer screening mandates and evidence-based surveillance intervals across multiple disease categories: the United States Preventive Services Task Force recommends colorectal cancer screening beginning at age 45, a guideline shift that expanded the eligible screening population by an estimated 21 million individuals. The diagnostic segment also benefits from AI-assisted lesion detection, which is improving adenoma detection rates and the clinical yield of individual procedures, providing reimbursement justification for more frequent monitoring intervals in high-risk populations.

Supply chain leads interviewed across 14 hospital gastroenterology and pulmonology departments in our Q3 2025 research indicated that 67% of facilities had formalized, or were in active procurement evaluation for, single-use scopes in at least one diagnostic endoscopy category a materially higher rate than the 39% documented in a comparable assessment conducted in Q1 2023, confirming a meaningful acceleration of adoption intent across the diagnostic segment of the disposable endoscopes industry.

Surgical

The surgical segment represented 38.19% of the disposable endoscopes market in 2025 approximately USD 840 million and carries the faster of the two clinical use CAGRs at 16% through 2035. This growth premium reflects the higher per-procedure revenue associated with therapeutic and interventional endoscopy, the expansion of endoscopic surgical indications enabled by next-generation single-use platforms, and the structural migration of minor endoscopic surgeries from inpatient operating rooms to ambulatory surgical settings. Key surgical applications include ERCP and cholangioscopy via single-use duodenoscopes, ureteroscopic lithotripsy via single-use ureteroscopes, bronchoscopic biopsy and therapeutic intervention, and operative hysteroscopy for endometrial and submucosal pathology.

The more consequential shift within this segment is the convergence of single-use endoscopy with therapeutic accessory ecosystems disposable biopsy forceps, retrieval baskets, and stone extraction devices designed for compatibility with specific single-use scope working channels which is elevating the procedural completeness of single-use surgical endoscopy and removing the historical need for reusable accessory components. The surgical segment's growth trajectory is further supported by favorable payment reform dynamics in the United States, where CMS has continued expanding the outpatient surgical procedures list to include endoscopic interventions historically reimbursed only in inpatient settings.^{[5]Centers for Medicare & Medicaid Services, cms.gov}

By End Use

Hospitals

Hospitals constitute the largest end-use category in the disposable endoscopes market, accounting for 63.81% of global revenue in 2025 approximately USD 1.40 billion and projected to advance at a CAGR of 15.5% through 2035. Within hospital settings, disposable endoscope adoption is concentrated across three primary clinical departments: pulmonology and critical care (bronchoscopy and laryngoscopy), gastroenterology and hepatology (upper GI endoscopy, ERCP, and colonoscopy), and urology (cystoscopy and ureteroscopy).

The hospital end-use segment benefits from the institutional infrastructure to manage high-procedure-volume endoscopy units, the procurement scale to negotiate favorable per-unit pricing through group purchasing organizations, and the compounding effect of regulatory and accreditation pressures that systematically incentivize infection control investment. Large academic medical centers and tertiary care hospitals particularly those with active transplant, oncology, and complex GI surgery programs have been the earliest and deepest adopters of single-use devices, driven by the intersection of high procedure volumes, elevated infection risk in immunocompromised patient populations, and robust clinical research programs generating the institutional evidence required for protocol-level adoption.

At the segment level, the procurement decision architecture in hospitals is more layered than in ambulatory settings: disposable endoscope adoption typically requires alignment across clinical leadership, infection control officers, supply chain directors, and value analysis committees a process that extends sales cycles but, once completed, tends to produce durable, multi-year supply commitments rather than transactional purchasing. The Vizient GPO partnership established by Ambu A/S in 2025 illustrates the strategic logic of this dynamic precisely: by securing formulary-level access across a national network of integrated delivery systems through a single GPO agreement, Ambu effectively converted a multi-account selling challenge into a platform-level procurement default for participating hospital members.

Federal health data indicates that approximately 15.2% of reusable duodenoscopes may retain viable microbial contamination even after enhanced cleaning protocols a statistic that has become a reference point in hospital value analysis committee deliberations across the United States and Western Europe, reinforcing the infection control case for single-use conversion at the institutional level. The hospital segment's CAGR of 15.5% reflects a mature but still-expanding penetration curve in North America and Europe, combined with accelerating initial adoption in emerging market hospital infrastructure across Asia Pacific and Latin America, where government-funded capacity expansion programs are increasing procedure volumes at secondary and tertiary care facilities.

Ambulatory Surgical Centers

Ambulatory surgical centers represent 28.40% of disposable endoscopes market revenue in 2025 approximately USD 625 million and project the fastest end-use CAGR at 16.3% through 2035, outpacing both the hospital and other end-user segments. The structural driver is the sustained, payer-incentivized global migration of GI, urological, and pulmonary procedures from hospital inpatient and outpatient departments to freestanding ASCs, where the total episode cost for equivalent procedures runs materially lower.

In the United States, CMS has progressively expanded the Ambulatory Surgical Center Covered Procedures List to include endoscopic interventions including complex ureteroscopy and upper GI procedures that were historically reimbursed exclusively in hospital outpatient settings, directly expanding the reimbursable procedure volume accessible to ASC operators. This reimbursement realignment has accelerated capital formation in the ASC sector, with major operators including USPI (Tenet Healthcare), Envision Healthcare, and SCA Health expanding their endoscopy suite capacity in response to rising outpatient demand across GI, urology, and pulmonology.

Disposable endoscopes are structurally better suited to ASC economics than to hospital environments for several compounding reasons. First, ASCs typically lack the centralized sterile processing infrastructure that makes reprocessing viable in hospital settings  single-use devices eliminate this capital and labor requirement entirely. Second, the rapid procedure turnaround required to maximize suite utilization in a fee-for-procedure revenue model is directly supported by single-use platforms, which reduce room reset time by eliminating the scope-out-for-reprocessing scheduling gap. Third, ASC regulatory compliance for infection control is governed by CMS Conditions for Coverage and state-level health department standards frameworks that increasingly reference FDA guidance on endoscope reprocessing risk and create institutional motivation to adopt devices that simplify compliance documentation.

In our survey of 45 ASC administrators across the United States conducted in H1 2025, 59% identified single-use endoscope adoption as a near-term operational priority, with reprocessing labor cost reduction and scheduling flexibility cited as the top two motivating factors ranked ahead of infection control, which placed third. This ordering reflects the ASC segment's distinctive value calculus: while infection control drives the hospital-level adoption case, operational efficiency is the more immediately legible economic argument for ASC procurement decision-makers operating under tighter margin constraints. Ambu's aBox 2 platform deployment across 14 procedure rooms at a multi-site US Midwest ASC operator in 2024 reducing per-room setup time by approximately 35 minutes per session quantifies the throughput economics that are accelerating single-use adoption in this channel.

Other End Users

The other end users segment encompassing specialist physician offices, outpatient clinics, military and defense medical facilities, urgent care centers, and veterinary medicine accounted for 7.79% of disposable endoscopes market revenue in 2025, approximately USD 171 million, with a projected CAGR of 14.2% through 2035. The comparatively modest growth rate relative to hospitals and ASCs reflects the structural complexity of penetrating fragmented, low-to-medium volume settings with device pricing and platform investments calibrated for high-volume institutional customers. That said, two sub-channels within this segment are exhibiting above-average growth momentum that warrants focused attention.

The first is physician office-based endoscopy, an expanding channel in the United States particularly in gastroenterology and urology private practices where the unit economics of single-use devices are increasingly favorable relative to maintaining reusable scope infrastructure in lower-volume settings. A gastroenterology practice performing 800–1,200 colonoscopies and upper GI procedures annually does not generate sufficient scope utilization to justify the capital investment, reprocessing labor, and quality assurance overhead of a hospital-grade endoscope reprocessing facility; single-use devices eliminate that fixed-cost structure entirely and shift the per-procedure economics toward a variable model that scales with patient volume.

The second is military and defense medicine: NATO member country medical corps including the US Army Medical Command and British Army Medical Services have adopted single-use bronchoscopes and laryngoscopes for forward operating base and field hospital deployment, where decontamination infrastructure is either unavailable or operationally impractical. The field-deployment use case maps directly onto the single-use value proposition  sterile, ready-to-use devices that require no on-site processing equipment and generate no reprocessing risk in austere medical environments. As these specialized procurement channels mature and as device pricing compresses incrementally with manufacturing scale, the other end users segment is expected to contribute a growing share of total disposable endoscopes industry volume through the latter half of the forecast period.

By Region

North America Disposable Endoscopes Market

North America holds the largest regional share of the disposable endoscopes market at 49.93% in 2025, equivalent to approximately USD 1.10 billion in revenue, advancing at a CAGR of 14.7% through 2035. The United States is the primary market within the region, driven by the world's most advanced single-use endoscope commercial infrastructure including the broadest portfolio of FDA-cleared devices, the most comprehensive group purchasing organization framework for hospital procurement, and a reimbursement environment increasingly aligned with outpatient endoscopic procedures.

The FDA's sustained regulatory attention to reusable duodenoscope contamination risk reflected in multiple safety communications and the agency's published preference for disposable alternatives in ERCP has created a strong institutional mandate for single-use conversion in high-risk procedure categories. Canada is an emerging secondary contributor, with provincial health systems in Ontario and British Columbia having incorporated single-use endoscopy preference criteria into infection control procurement guidelines effective 2024. The US market's adoption maturity in bronchoscopy where Ambu estimates single-use penetration at approximately 70% of procedure volume in established accounts suggests the near-term growth frontier will shift toward GI endoscopy, ureteroscopy, and the ASC channel as the North America market's primary incremental volume drivers through 2028.

Europe Disposable Endoscopes Market

Europe accounted for 33.33% of disposable endoscopes industry revenue in 2025 approximately USD 733 million projecting a CAGR of 15.2% through 2035. At the regional level, the market is bifurcated between an advanced northern and western tier Germany, the United Kingdom, France, the Netherlands, and the Nordics where single-use adoption is accelerating on the back of national infection control mandates and institutional procurement programs, and a developing southern and eastern tier Spain, Italy, Poland, Czech Republic where adoption is at an earlier stage and reimbursement coverage remains inconsistent.

Germany represents the region's largest national market; hospital hygiene regulations under the Krankenhaushygienegesetz and RKI infection control guidelines have created a regulatory environment broadly supportive of single-use endoscope adoption. In the United Kingdom, NHS Supply Chain's Medical Technology Managed Service framework has incorporated single-use bronchoscopes and laryngoscopes into formulary access agreements, lowering procurement friction for NHS trusts considering conversion. The EU Medical Device Regulation (MDR 2017/745), fully applicable since May 2021, has raised post-market surveillance and clinical evidence requirements for all endoscopic devices sold in the EU a compliance burden that reinforces the competitive position of established, well-capitalized firms with robust regulatory teams. Pentax Medical's January 2025 European commercial launch of the ONE Pulmo single-use bronchoscope signals continued product pipeline investment in the region.

Rest of World Disposable Endoscopes Market

The Rest of World region dominated by Asia Pacific in terms of current procedure volumes and investment momentum accounted for 16.74% of global disposable endoscopes revenue in 2025, approximately USD 368 million, and is projected to advance at a CAGR of 18.7% through 2035, the highest of any regional segment. Within Asia Pacific, China represents the largest national market by procedure volume and manufacturing capacity, with domestic producers including HugeMed, Vathin Medical, UE Medical, and TSC serving the domestic market while competing in Southeast Asian export markets at price points structurally below Western competitors.

India is the region's most consequential growth opportunity: the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) scheme has expanded health coverage to approximately 500 million individuals, creating a reimbursed demand base for diagnostic endoscopy procedures at secondary and tertiary care hospitals that has grown substantially since 2023. Japan and South Korea occupy a technology-differentiated position within the region Japanese manufacturers, including Olympus, are leveraging endoscopy heritage to develop next-generation single-use platforms targeting advanced diagnostic indications, while South Korean health systems are selectively adopting single-use bronchoscopes and duodenoscopes under the National Health Insurance Service's technology assessment framework in procedures where contamination liability has been formally recognized.

Disposable Endoscopes Market Share

The disposable endoscopes industry is moderately concentrated, with the top five participants Ambu A/S, Boston Scientific Corporation, Olympus Corporation, Hoya Corporation (PENTAX Medical), and Karl Storz SE & Co. KG collectively accounting for approximately 65% of global revenue in 2025. The remaining 35% of the market is distributed across a diverse field of specialty and regional players, including Verathon, Coloplast, CooperSurgical, Flexicare, and a growing cohort of Chinese manufacturers that are reshaping volume economics at the lower end of the market.

Ambu A/S retains the leading individual position at approximately 30% global share a position built on first-mover advantage in single-use bronchoscopy, a portfolio spanning bronchoscopy, urology, GI, laryngoscopy, and ENT, and a proprietary digital integration platform (aView 2 Advance, aBox 2) that creates meaningful switching costs at the facility level by embedding Ambu's devices into procedure room infrastructure.

The company's commercial strategy has evolved from product-level selling to platform-level account management, prioritizing total procedural coverage within target hospital accounts and leveraging strategic agreements such as the Vizient GPO partnership to establish formulary access at scale. At the J.P. Morgan Healthcare Conference in January 2026, Ambu management reaffirmed its long-term growth target of 11–13% overall revenue CAGR through 2030, with the endoscopy segment expected to outperform at 15–20% CAGR, signaling sustained confidence in the disposable endoscopes market's penetration opportunities.

Boston Scientific Corporation is the most consequential direct competitor in the GI endoscopy sub-market, anchored by the EXALT Model D single-use duodenoscope which occupies a dominant position in ERCP single-use conversion at high-volume GI centers in the United States. Boston Scientific's competitive strength is rooted in its established relationships with GI specialists and its ability to bundle the EXALT platform within a broader procedural solutions portfolio spanning stents, hemostasis devices, and diagnostic accessories. The FDA clearance for an updated EXALT Model D configuration in March 2025 reinforced the company's clinical validation narrative and maintained its lead position in the duodenoscope sub-category.

Olympus Corporation represents a structurally distinct competitive dynamic within the disposable endoscopes market: a historically dominant reusable endoscope manufacturer executing a managed transition into single-use platforms to protect its installed base. Olympus's RenaFlex single-use flexible ureteroscope, FDA-cleared in April 2024, and its exclusive global distribution partnership with MacroLux Medical for single-use urology products, announced in September 2025, signal the company's intent to build a credible single-use urology portfolio alongside its reusable stronghold.

The inherent tension in Olympus's position protecting a high-margin reusable device business while investing in its single-use replacement makes its competitive trajectory more complex to sustain than Ambu's single-use-pure-play model. Hoya Corporation, through its PENTAX Medical subsidiary, holds a focused position in single-use bronchoscopy; the European launch of the ONE Pulmo in January 2025 reflects Hoya's intent to establish a bronchoscopy-led beachhead from which to expand into GI and urology. Karl Storz's FIVE S 6.5 bronchoscope, FDA-cleared in March 2026, represents the newest entrant to the upper-tier competitive field, positioned specifically for the critical care and ICU segment a clinically demanding and commercially valuable niche where performance differentiation on working channel diameter and suction capacity drives physician procurement preference.

At the mid-market level, Verathon a Roper Technologies subsidiary has maintained a commercially significant position in single-use bronchoscopy with the B-Flex platform, evaluated positively in peer-reviewed comparative studies. Chinese manufacturers Vathin Medical, HugeMed, UE Medical, and TSC are expanding share in emerging markets and beginning to address lower-tier procurement in European and Southeast Asian markets, representing a mid-term competitive threat to Western manufacturers' volume economics in price-sensitive segments. Their combined presence in the disposable endoscopes industry reinforces the bifurcated competitive structure: a premium tier dominated by established Western players competing on platform integration and clinical validation, and a volume tier where Chinese manufacturers compete on unit economics and access-market pricing.

Disposable Endoscopes Market Companies

Major players operating in the disposable endoscopes industry are:

Ambu A/S — The Danish medtech company is the global pioneer and market leader in single-use endoscopy, with a history in disposable devices dating to the 1950s. Its commercial strategy centers on building the broadest single-use endoscopy portfolio in the disposable endoscopes industry spanning bronchoscopy, urology, GI, video laryngoscopy, and ENT unified under the aView 2 Advance and aBox 2 digital imaging platforms. Ambu sells through a direct-to-hospital commercial model in the United States, Western Europe, and Japan, supplemented by distributor partnerships in emerging markets. With single-use endoscopy contributing approximately 30% of group revenue as of Q2 FY2025/26 and management targeting 15–20% CAGR in the endoscopy segment, the company is executing a sustained organic growth strategy focused on account deepening, procedural penetration in underconverted categories (notably GI), and clinical evidence generation to support adoption in protocol-driven health systems.

Boston Scientific Corporation — Boston Scientific's disposable endoscopy strategy is anchored in the EXALT single-use endoscope platform, with the EXALT Model D duodenoscope serving as the company's most commercially significant single-use device. Boston Scientific bundles EXALT within its broader GI procedural portfolio stents, tissue sampling, hemostasis creating an integrated account relationship that is difficult to displace on price alone at established accounts. The company is investing in expanding its single-use portfolio beyond duodenoscopy into bronchoscopy via the Exalt Model B and urology, broadening its presence in the disposable endoscopes industry.

Olympus Corporation — Olympus is the world's largest endoscope manufacturer by installed base, with a dominant position in the conventional reusable market across all device categories. Its entry into the disposable endoscopes market represents a managed cannibalization of its own installed base, a strategic necessity as market conversion accelerates. The RenaFlex single-use ureteroscope and H-SteriScope single-use bronchoscope are its most commercially active single-use platforms. The September 2025 distribution agreement with MacroLux Medical for single-use urology products signals willingness to supplement the internal single-use pipeline with partnership-based access to complementary product categories.

Hoya Corporation (PENTAX Medical) — Hoya operates its medical device business through PENTAX Medical, one of the established triad of global endoscope manufacturers alongside Olympus and Fujifilm. PENTAX Medical's single-use portfolio is anchored by the ONE Pulmo bronchoscope, and the company is investing in CE mark and FDA clearance pathways for additional single-use platforms. Hoya's broader optics and sensing technology capabilities provide a differentiated R&D basis for next-generation imaging integration in single-use devices within the disposable endoscopes market.

Karl Storz SE & Co. KG — Karl Storz is a German-headquartered endoscopy and minimally invasive surgery specialist with a strong position in rigid and semi-rigid endoscopy, laparoscopy, and ENT. Its FIVE product family of which the FIVE S 6.5 bronchoscope, FDA-cleared in March 2026, is the most recently commercialized reflects the company's investment in single-use flexible endoscopy for the critical care and proceduralist market. Close relationships with operating room and critical care clinical communities in Germany and across Europe position Karl Storz to drive adoption in institutional settings that value its engineering credentials.

Coloplast — Coloplast is a Danish medical device company with a core business in continence care and wound management. Its disposable endoscopy participation centers on urology, with competencies in minimally invasive urological procedures that are adjacent to the disposable cystoscope and ureteroscope categories. The company serves hospital and community urology settings across Europe and North America.

CooperSurgical — CooperSurgical, a division of The Cooper Companies, focuses on women's health and fertility a positioning that maps directly onto single-use hysteroscopy. Its TRUCLEAR Hysteroscopic Morcellation System is an established platform in operative hysteroscopy, and the company has invested in single-use compatible components that support ambulatory and office-based gynecological procedure workflows within the broader disposable endoscopes market.

Flexicare — Flexicare is a UK-based manufacturer of critical care and airway management products. Its disposable endoscopy presence is concentrated in the bronchoscopy and laryngoscopy categories, serving emergency medicine, anesthesia, and intensive care departments in the United Kingdom and international markets. The company operates through a distributor-led model in most international territories.

HugeMed — HugeMed is a Chinese medical device company producing a range of single-use flexible endoscopes for the bronchoscopy and urology markets. The company has pursued regulatory clearances through China's NMPA and international markets and represents one of the more commercially scaled Chinese competitors in the domestic and Southeast Asian export segments of the disposable endoscopes industry.

RICHARD WOLF — RICHARD WOLF is a German medical device manufacturer with deep engineering expertise in endoscopy, urology, and minimally invasive surgery. The company produces both reusable and single-use endoscopic devices and serves hospital and specialist clinic customers primarily in Germany and across the European Union.

TSC (Tiansong Medical) — TSC is a Chinese manufacturer of single-use flexible endoscopes competing in the domestic Chinese market and selected international markets. Its product portfolio covers bronchoscopes and cystoscopes designed for cost-sensitive procurement environments, with a commercial positioning oriented toward secondary and tertiary hospital procurement in emerging markets.

UE Medical — UE Medical is a Chinese medical device company specializing in single-use endoscopes and minimally invasive surgical instruments. The company has built a portfolio of single-use bronchoscopes, ureteroscopes, and cystoscopes targeting Chinese hospital procurement and, increasingly, Southeast Asian export channels establishing a presence in the faster-growing tier of the disposable endoscopes market.

Vathin Medical — Vathin Medical (Hunan Vathin Medical Instrument Co., Ltd.) is one of the more internationally visible Chinese single-use endoscope manufacturers, with products including flexible bronchoscopes and gastroscopes that have received CE mark approval in Europe. Vathin competes primarily on price and is positioned as an access-market alternative to premium Western brands in cost-sensitive hospital procurement contexts across the disposable endoscopes industry.

Verathon — Verathon, a Roper Technologies subsidiary, is a US-based medical device manufacturer best known for its BladderScan bladder ultrasound and GlideScope video laryngoscope platforms. In the disposable endoscopes market, Verathon's B-Flex single-use flexible bronchoscope  evaluated positively in peer-reviewed comparative studies is its primary commercial offering, targeting ICU, critical care, and bronchoscopy unit procurement in the United States and Western Europe.

Disposable Endoscopes Industry News

• Mar 2026: Karl Storz received FDA 510(k) clearance for the FIVE S 6.5 single-use bronchoscope, engineered with a 3 mm working channel for critical care airway management in ICU and high-acuity emergency settings.
• Feb 2026: LoopView received FDA 510(k) clearance for the B27-C single-use digital flexible bronchoscope, expanding the competitive field in ICU-targeted disposable bronchoscopy in North America.
• Jan 2026: Ambu A/S reaffirmed its long-term growth strategy at the J.P. Morgan Healthcare Conference in San Francisco, projecting 15–20% CAGR for its endoscopy segment through 2030, with bronchoscopy as the established revenue engine and gastroenterology identified as the next major penetration opportunity.
• Sep 2025: Zenflow received FDA 510(k) clearance for the Zenflow Spring Scope, the first single-use cystoscope featuring a 12 French working channel over 80% larger than prior single-use models enabling expanded therapeutic urological applications in a fully disposable format.
• Sep 2025: UroViu Corporation received FDA 510(k) clearance for the UV5000 cordless single-use endoscope platform, featuring enhanced HD visualization, extended battery life, and Wi-Fi connectivity, replacing its UV4500 predecessor in the US market.
• Sep 2025: Olympus Corporation announced an exclusive global distribution agreement with MacroLux Medical Technology to distribute single-use urology products, marking a material expansion of Olympus's single-use commercial presence in the disposable endoscopes market.
• Jun 2025: Ambu A/S received expanded FDA 510(k) clearance for the aScope 5 Cysto HD, making it the first single-use flexible cysto-nephroscope cleared for percutaneous nephrolithotomy procedures in the United States.
• Mar 2025: Boston Scientific received FDA clearance for an updated configuration of the EXALT Model D single-use duodenoscope, reinforcing its clinical validation narrative for ERCP single-use conversion.
• Feb 2025: Ambu A/S launched the aScope 5 Broncho HD, a high-definition single-use bronchoscope with a 5.6 mm insertion tube and 2.8 mm working channel, advancing HD imaging parity with reusable systems in routine pulmonology and ICU bronchoscopy.
• Jan 2025: Pentax Medical (Hoya Group) announced the European commercial launch of its ONE Pulmo single-use bronchoscope, targeting NHS-affiliated hospital and pulmonology department procurement across the United Kingdom and Northern Europe.
• Nov 2024: Valens Semiconductor launched the VA7000 chipset, a purpose-built imaging processor for next-generation single-use endoscopes, delivering 4K-class image processing within the thermal and power constraints of disposable device formats.

• Apr 2024: Olympus Corporation received FDA clearance for the RenaFlex single-use flexible ureteroscope system, establishing the company's first commercially significant disposable product in the urological stone management category.

Market Concentration Score

The disposable endoscopes market scores 6 out of 10 on the concentration scale, reflecting a moderately consolidated upper tier with five players commanding approximately 65% of global revenue and a single firm (Ambu A/S) holding ~30% share offset by a fragmented mid-and-lower tier comprising more than 30 regional and specialty competitors, including an expanding cohort of Chinese domestic manufacturers exerting meaningful competitive pressure on volume economics.

The disposable endoscopes market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Bronchoscopes
• Cystoscopes
• Duodenoscopes
• Hysteroscopes
• Laryngoscopes
• Ureteroscopes
• Other product types

Market, By Clinical Use

• Diagnostic
• Surgical

Market, By End Use

• Hospital
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Netherlands
  • Spain
  • Italy
• RoW